<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335892">
  <stage>Registered</stage>
  <submitdate>25/08/2010</submitdate>
  <approvaldate>7/09/2010</approvaldate>
  <actrnumber>ACTRN12610000747022</actrnumber>
  <trial_identification>
    <studytitle>Improving the diagnosis of liver cancer with Positron Emission Tomography (PET) scanners by applying mathematical models and using breathing motion correction methods</studytitle>
    <scientifictitle>Use of kinetic analysis and respiratory gating of Positron Emission Tomography (PET) scans to increase the sensitivity for detection of liver metastases in colon cancer prior to attempted curative surgery.</scientifictitle>
    <utrn>U1111-1116-7009</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colon cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>PET scanning, kinetic analysis, respiratory motion correction. This involves 60 additional minutes of PET scanning (after the routine PET tracer injection up until the usual time of commencement of the routine PET scan at 60 minutes post injection). The information for kinetic analysis and respiratory motion correction are obtained during this 60 minute scan.</interventions>
    <comparator>Standard images obtained from a routine clinical PET scan</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of F18-Flourodexoyglucose (FDG) avid cancer secondaries detected in the liver with the modified method compared with standard FDG PET imaging.</outcome>
      <timepoint>Baseline only</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Previous colon cancer, known or suspected colon cancer metastases in the liver, referred for routine PET scan as part of their clinical workup, able to lie in PET scanner for additional 60 minutes</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to undergo PET scanning</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Paul Thomas</primarysponsorname>
    <primarysponsoraddress>Royal Brisbane and Women's Hospital
Butterfield Street
Herston 4029
Queensland</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Brisbane and Women's Hospital</fundingname>
      <fundingaddress>Butterfield Street
Herston 4029
Queensland</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Brisbane and Women's Hospital</sponsorname>
      <sponsoraddress>Butterfield Street
Herston 4029
Queensland</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Jye Smith</othercollaboratorname>
      <othercollaboratoraddress>Royal Brisbane and Women's Hospital
Butterfield Street
Herston 4029
Queensland</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr David Macfarlane</othercollaboratorname>
      <othercollaboratoraddress>Royal Brisbane and Women's Hospital
Butterfield Street
Herston 4029
Queensland</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is aimed at improved PET scanning diagnosis of liver secondaries from colon cancer. There will be no recruitment of patients from outside of the Royal Brisbane and Women's Hospital.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital Institutional Review Board</ethicname>
      <ethicaddress>Royal Brisbane and Women's Hospital
Butterfield Street
Herston 4029
Queensland</ethicaddress>
      <ethicapprovaldate>21/09/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Thomas</name>
      <address>Royal Brisbane and Women's Hospital
Department of Nuclear Medicine
Butterfield Street
Herston 4029
Queensland</address>
      <phone>+ 61 7 3636 7593</phone>
      <fax />
      <email>paul.thomas@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Thomas</name>
      <address>Royal Brisbane and Women's Hospital
Butterfield Street
Herston 4029
Queensland</address>
      <phone>+ 61 7 3636 7593</phone>
      <fax />
      <email>rbwh-nuclear-medicine-department@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>